BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36566690)

  • 21. Accuracy and Limitations of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients with Positive Nodes.
    Aragon-Sanchez S; Oliver-Perez MR; Madariaga A; Tabuenca MJ; Martinez M; Galindo A; Arroyo ML; Gallego M; Blanco M; Ciruelos-Gil EM
    Breast J; 2022; 2022():1507881. PubMed ID: 36051467
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validation of the targeted axillary dissection technique in the axillary staging of breast cancer after neoadjuvant therapy: Preliminary results.
    Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
    Surg Oncol; 2019 Sep; 30():52-57. PubMed ID: 31500785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a predictive score of axillary lymph node dissection based on targeted axillary dissection in patients with breast cancer diagnosis, affected lymph nodes, and neoadjuvant treatment.
    Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
    Surg Oncol; 2021 Sep; 38():101629. PubMed ID: 34171793
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic accuracy of de-escalated surgical procedure in axilla for node-positive breast cancer patients treated with neoadjuvant systemic therapy: A systematic review and meta-analysis.
    Song YX; Xu Z; Liang MX; Liu Z; Hou JC; Chen X; Xu D; Fei YJ; Tang JH
    Cancer Med; 2022 Nov; 11(22):4085-4103. PubMed ID: 35502768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer.
    Enokido K; Watanabe C; Nakamura S; Ogiya A; Osako T; Akiyama F; Yoshimura A; Iwata H; Ohno S; Kojima Y; Tsugawa K; Motomura K; Hayashi N; Yamauchi H; Sato N
    Clin Breast Cancer; 2016 Aug; 16(4):299-304. PubMed ID: 26993216
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.
    Kuehn T; Bauerfeind I; Fehm T; Fleige B; Hausschild M; Helms G; Lebeau A; Liedtke C; von Minckwitz G; Nekljudova V; Schmatloch S; Schrenk P; Staebler A; Untch M
    Lancet Oncol; 2013 Jun; 14(7):609-18. PubMed ID: 23683750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted axillary dissection after neoadjuvant chemotherapy for highly selective patients with initial cN1 breast cancer: A single-center prospective trial.
    Chen X; Lu Z; Wang C; Lyu M; Qiao J; Sun X; Li L; Zhang C; Liu Z
    Chin Med J (Engl); 2024 Jun; 137(12):1421-1430. PubMed ID: 38557731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance).
    Boughey JC; Ballman KV; Le-Petross HT; McCall LM; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Feliberti EC; Hunt KK
    Ann Surg; 2016 Apr; 263(4):802-7. PubMed ID: 26649589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted Axillary Dissection with
    Munck F; Andersen IS; Vejborg I; Gerlach MK; Lanng C; Kroman NT; Tvedskov THF
    Ann Surg Oncol; 2023 Jul; 30(7):4135-4142. PubMed ID: 37062781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of axillary ultrasound (AUS) to assess the nodal status after neoadjuvant chemotherapy (NACT) in primary breast cancer patients.
    Leinert E; Lukac S; Schwentner L; Coenen A; Fink V; Veselinovic K; Dayan D; Janni W; Friedl TWP
    Surg Oncol; 2024 Feb; 52():102016. PubMed ID: 38056112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patients with initial nodal involvement due to breast cancer who have received neoadjuvant chemotherapy: Combined sentinel node-radioguided surgery of the pathological node.
    Fuertes Manuel J; Kohan S; Jordà Solé M; Mateu Hidalgo I; Miralles Curto M; Aguiló Sagristà O; Aguilar Alomá E; Peña González K; Lafuerza Torres A; Melé Olivé M; Repkova J; Montero Jaime MJ; Gumà Padró J
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2022; 41(5):284-291. PubMed ID: 35597764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer.
    Cox CE; Cox JM; White LB; Stowell NG; Clark JD; Allred N; Meyers M; Dupont E; Furman B; Minton S
    Ann Surg Oncol; 2006 Apr; 13(4):483-90. PubMed ID: 16523361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients.
    El Hage Chehade H; Headon H; El Tokhy O; Heeney J; Kasem A; Mokbel K
    Am J Surg; 2016 Nov; 212(5):969-981. PubMed ID: 27671032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patterns in the Use of Axillary Operations for Patients with Node-Positive Breast Cancer After Neoadjuvant Chemotherapy: A National Cancer Database (NCDB) Analysis.
    Srour MK; Tseng J; Luu M; Alban RF; Giuliano AE; Chung A
    Ann Surg Oncol; 2019 Oct; 26(10):3305-3311. PubMed ID: 31342364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The predictive value of sentinel node biopsy in early breast cancer after neo-adjuvant chemotherapy: A prospective study.
    Najim O; Dockx Y; Huyghe I; van den Wyngaert T; Papadimitriou K; Tjalma WAA; Huizing MT
    Eur J Obstet Gynecol Reprod Biol; 2018 Oct; 229():108-111. PubMed ID: 30145524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Wire guided localisation for targeted axillary node dissection is accurate in axillary staging in node positive breast cancer following neoadjuvant chemotherapy.
    Balasubramanian R; Morgan C; Shaari E; Kovacs T; Pinder SE; Hamed H; Sever AR; Kothari A
    Eur J Surg Oncol; 2020 Jun; 46(6):1028-1033. PubMed ID: 31879050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Would Removal of All Ultrasound Abnormal Metastatic Lymph Nodes Without Sentinel Lymph Node Biopsy Be Accurate in Patients with Breast Cancer with Neoadjuvant Chemotherapy?
    Lim GH; Gudi M; Teo SY; Ng RP; Yan Z; Lee YS; Allen JC; Leong LCH
    Oncologist; 2020 Nov; 25(11):e1621-e1627. PubMed ID: 32537791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radio-isotope occult lesion localization (ROLL) techniques to identify the clipped node for targeted axillary dissection (TAD) in breast cancer.
    Winder AA; Spillane AJ; Sood S; McKessar M; Cohn D; Snook K
    ANZ J Surg; 2022 Nov; 92(11):3017-3021. PubMed ID: 36262092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The problem of axillary staging in breast cancer after neoadjuvant chemotherapy. Role of targeted axillary dissection and types of lymph node markers.
    Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Aguayo-Albasini JL
    Cir Esp (Engl Ed); 2020 Nov; 98(9):510-515. PubMed ID: 32386728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sentinel Node Biopsy Versus Low Axillary Sampling in Predicting Nodal Status of Postchemotherapy Axilla in Women With Breast Cancer.
    Parmar V; Nair NS; Vanmali V; Hawaldar RW; Siddique S; Shet T; Desai S; Rangarajan V; Patil A; Gupta S; Badwe RA
    JCO Glob Oncol; 2020 Oct; 6():1546-1553. PubMed ID: 33074737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.